Compare Dyne Therapeutics Inc. Common Stock (DYN) vs State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF (FLRN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.08 (market cap $2.86B), while State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF trades at $30.77 (market cap $3.10B). The key difference: Dyne Therapeutics Inc. Common Stock and State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF are close in size by market cap, and State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF is trading nearer its 52-week high, Dyne Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF for 17 Days on average.
| DYN | FLRN | |
|---|---|---|
Market Cap | $2.86B | $3.10B |
Volume | 3,341,579 | 1,095,314 |
Sector | Health | Fixed Income |
52-Week High | $26.78 | $30.86 |
52-Week Low | $14.60 | $30.65 |
Typical Hold Time | 0 Days | 17 Days |
Enterprise Value | $2.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
FLRN, the SPDR Bloomberg Investment Grade Floating Rate ETF, trades at $30.77 with no recent price change. Technical indicators signal a bearish trend, while recent news highlights its appeal as a floating-rate bond ETF amid rising interest rates. The ETF has announced several small dividends for 2026, but key financial ratios like P/E and P/B are unavailable.
The outlook for FLRN is mixed; its near-zero duration and floating-rate structure offer protection against rate hikes, attracting institutional interest. However, significant financial sector exposure and bearish technical signals pose risks. Investors should weigh the defensive characteristics against market volatility and sector-specific headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF
FLRN invests in U.S. dollar-denominated investment-grade floating rate notes with maturities under five years. It provides exposure to corporate and supranational debt whose interest payments adjust with market rates, helping to mitigate interest rate risk.
Read more on FLRN →
